Energy Specific Far Infrared Radiation Treatment for AIDS
Recruitment status was: Active, not recruiting
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for HIV/AIDS|
- The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 15μm wavelength) on HIV/AIDS. [ Time Frame: One year ]
|Study Start Date:||February 2008|
|Estimated Study Completion Date:||November 2009|
|Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
Infrared Radiation, wavelength between 5 and 20 microns
Radiation: Far infrared
Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
Acquired immune deficiency syndrome or acquired immunodeficiency syndrome (AIDS or Aids) is a collection of symptoms and infections resulting from the specific damage to the immune system caused by the human immunodeficiency virus (HIV) in humans. The late stage of the condition leaves individuals prone to opportunistic infections and tumors. Although treatments for AIDS and HIV exist to slow the virus' progression, there is no known cure.
The investigators are postulating that energy specific electromagnetic radiation of the central nervous system, the viscera and the endocrine system has the potential to enhance the immune system; thereby enhancing the production of CD4+ T cells and other killer cells to fight and destroy the human immunodeficiency virus.
The primary end point is to determine the therapeutic effects of far infrared radiation (5μm to 20μm wavelength) on HIV/AIDS.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00574522
|The Centre for Incurable Diseases|
|Toronto, Ontario, Canada, M4V 1L5|
|Principal Investigator:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|
|Study Director:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|